Nature materialsMar 18, 2026

Specially linked charged lipids change immune cell metabolism to improve mRNA vaccines

mRNA Technology Weekly Brief ↗PubMed ↗DOI ↗

Updated Jun 27, 2026

Abstract

Essence

A crosslinked ionizable lipid made mRNA LNPs act as both delivery vehicles and dendritic-cell metabolic modulators.

Evidence

This was a formulation and preclinical vaccine-platform study in dendritic-cell, SARS-CoV-2 pseudovirus, and OVA cancer vaccine models, where C12-2aN LNPs promoted mRNA expression and glycolysis, improved neutralization and survival versus control LNPs, and had lower off-target delivery and immunogenicity than FDA-approved LNPs.

Caveat

The evidence comes from model vaccine systems, so human efficacy, dosing, and safety are outside the abstract's scope.

Simplified

Modulating metabolism in immune cells is an effective approach to induce desired immune responses. Here we develop a lipid nanoparticle (LNP) capable of metabolic reprogramming of dendritic cells for mRNA vaccine applications. Using imidoester-based conjugation chemistry, we design a crosslinked ionizable lipid, C12-2aN, which possesses intrinsic metabolic modulatory properties. This multifunctional ionizable lipid not only promotes effective mRNA expression by facilitating endosomal escape but also stimulates glycolysis through mTORC2 pathway activation. As both an mRNA carrier and a metabolic modulator, C12-2aN LNPs lead to potent vaccine efficacy in both SARS-CoV-2 and OVA cancer vaccine models, resulting in stronger neutralization of pseudovirus infection and improved survival rates, respectively, compared with control LNPs without the crosslinker. Moreover, C12-2aN LNPs outperformed FDA-approved LNPs in terms of reduced off-target delivery and lower immunogenicity. Overall, the integration of mRNA delivery and metabolic reprogramming induced by the ionizable lipid component presents significant potential for next-generation mRNA LNP vaccines.